Pricing Log in Create free account

Heron Therapeutics, Inc. (HRTX) vs Kalaris Therapeutics Inc. (KLRS)

Heron Therapeutics, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Heron Therapeutics, Inc. and Kalaris Therapeutics Inc. are of similar size ($53.2M and $51.6M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −22.5%) and the higher return on invested capital (0.00% vs −6.35%). Across the 14 metrics below, Kalaris Therapeutics Inc. leads on 8 and Heron Therapeutics, Inc. on 6.

Valuation

Metric HRTX KLRS Biotechnology median
P/E n/m n/m 10.60
P/S 0.37 n/m 9.40
P/B 9.42 1.01 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.33 0.66
EV/Sales 1.03 n/m 9.02
Earnings yield (65.52%) (85.64%) (32.88%)
Free cash flow yield (21.90%) (70.40%) (23.13%)

Profitability

Metric HRTX KLRS Biotechnology median
Gross margin 70.07% 0.00% 68.51%
Operating margin (7.19%) 0.00% 0.00%
Net margin (22.52%) 0.00% 0.00%
Free cash flow margin (8.00%) 0.00% 0.00%
Return on equity 318.21% (79.91%) (51.96%)
Return on assets (14.06%) (46.02%) (46.06%)
Return on invested capital (6.35%) 0.00% 0.00%

Growth

Metric HRTX KLRS Biotechnology median
Revenue growth (TTM) 0.99% — 6.76%
EPS growth (last fiscal year) (33.33%) 94.50% 29.88%
Revenue growth, 5-year CAGR 11.81% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HRTX KLRS Biotechnology median
Debt to equity 20.65 0.00 0.00
Current ratio 2.49 10.98 4.97
Net debt to EBITDA (643.88) 2.54 1.01

Dividend

Metric HRTX KLRS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HRTX KLRS Biotechnology median
Market cap 53.16m 51.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack